ghk cu danger GHK-CU – Research Peptide GHK-Cu Research Peptide Australia |

This is precisely where the combination with microneedling becomes clinically meaningful, and why we approach GHK-Cu both as an injectable and as a post-needling topical

64 OishiK.OhkuraN.WakabayashiM.ShiraiH.SatoK.MatsudaJ.et al (2006)

doi: 10.1242/jcs.075770 40 GentleIEWongWWEvansJMBankovackiACookWDKhanNRet al

CJC-1295 no DAC: 0.1mg Ipamorelin: 0.15mg BPC-157: 0.25mg GHK-Cu: 1mg CJC-1295 no DAC: 0.1mg Ipamorelin: 0.15mg BPC-157: 0.25mg (optional second dose) TB-500: 2.5mg during loading, 2mg maintenance Tirzepatide: Per prescribed escalation schedule This protocol requires significant commitment to injection frequency but addresses all major concerns simultaneously

Although the ability of PrP to bind Cu and operate as an endocytic Cu transporter is well documented 27,28 , this protein has not been considered as an important player in WD pathogenesis and in hepatic Cu metabolism in general